Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera ...

Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy hold back sales at the pharma giant.

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk lowered its full-year profit forecast on Wednesday in an early blow to the ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk on Wednesday reported third-quarter sales growth of 15%, beating forecasts in ...

Pfizer on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster ...

The White House is nearing an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some of their ...

The first lawsuit, filed on Friday, claims Novo's bid breaches Pfizer's merger agreement and seeks to bypass antitrust review ...

The revised bids are the latest unusual twist in the fight between big drugmakers over drug developer Metsera.

Novo Nordisk is continuing to lose ground in the obesity and diabetes markets, with the Danish drugmaker saying it expected ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk on Wednesday reported third-quarter sales growth of 11%, in line with ...

The White House is nearing an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some of their ...

Denmark's Novo Nordisk, the maker of Ozempic and Wegovy obesity drugs, said on Wednesday it was lowering its 2025 outlook for the third time this year, after posting tepid third-quarter results.